Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Investopedia on MSN23h
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Novo Shares Hits 9-Month Low as 2025 Guidance Underwhelms
MILAN (Reuters) - Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong ...
CBS News on MSN3d
Novo Nordisk's obesity-fighting drugs are fattening Denmark's economy while shrinking other sectors
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...
Reuters on MSN20h
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
FierceBiotech1d
Novo Nordisk discards kidney disease drug from $1.3B deal in wake of phase 3 fail
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1 ...
Novo Nordisk CFO says 2025 sales could see high-teens percentage growth
Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk ...